Details for Patent: 12,011,434
Which drugs does patent 12,011,434 protect, and when does it expire?
Patent 12,011,434 protects OGSIVEO and is included in one NDA.
This patent has eighty patent family members in twenty-nine countries.
Summary for Patent: 12,011,434
| Title: | Treatments with nirogacestat |
| Abstract: | The present disclosure relates to improved methods of treatment with nirogacestat. |
| Inventor(s): | Allison Lim, Shinta CHENG, Todd Webster SHEARER, Rex WILLIAMS, Kristin Patterson |
| Assignee: | SpringWorks Therapeutics Inc |
| Application Number: | US18/491,323 |
|
Patent Claim Types: see list of patent claims | Use; Dosage form; |
Drugs Protected by US Patent 12,011,434
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-001 | Nov 27, 2023 | DISCN | Yes | No | 12,011,434 | ⤷ Start Trial | TREATMENT OF ADULT PATIENTS WITH PROGRESSING DESMOID TUMORS | ⤷ Start Trial | ||||
| Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-002 | Apr 4, 2024 | RX | Yes | No | 12,011,434 | ⤷ Start Trial | TREATMENT OF ADULT PATIENTS WITH PROGRESSING DESMOID TUMORS | ⤷ Start Trial | ||||
| Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-003 | Apr 4, 2024 | RX | Yes | Yes | 12,011,434 | ⤷ Start Trial | TREATMENT OF ADULT PATIENTS WITH PROGRESSING DESMOID TUMORS | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,011,434
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 4010322 | ⤷ Start Trial | CA 2026 00017 | Denmark | ⤷ Start Trial |
| European Patent Office | 4010322 | ⤷ Start Trial | 301374 | Netherlands | ⤷ Start Trial |
| European Patent Office | 4010322 | ⤷ Start Trial | C20260011 | Finland | ⤷ Start Trial |
| European Patent Office | 4010322 | ⤷ Start Trial | LUC50046 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 4010322 | ⤷ Start Trial | PA2026516 | Lithuania | ⤷ Start Trial |
| European Patent Office | 4010322 | ⤷ Start Trial | 122026000026 | Germany | ⤷ Start Trial |
| European Patent Office | 4010322 | ⤷ Start Trial | 2026C/718 | Belgium | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
